
Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.
Founder and Owner
Aracana Life Sciences

Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.

Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.

Pharma manufacturing and development experts reassess their 2026 predictions for the industry and look ahead to the second half of the year.

Six months in, pharma manufacturing and development experts reassess their 2026 outlooks and predict what comes next.

Arcana Life Sciences' Remco Munnik revisits his 2026 predictions on EU regulatory reform, AI adoption, and data governance, and previews pharma's biggest challenges for H2 2026.

August 3rd 2026